Pancreatic Cancer Clinical Trials

25 trials recruiting in Canada.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

17 trials

Comparing 3 approaches for pancreatic ductal adenocarcinoma (PDAC)

Explore this study →

There are 3 groups in this study. Group A receives VS-7375. Groups B and C receive VS-7375, together with one or more of: cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction).

2 sites in Toronto

Phase 2
3 groups
2 sites in Toronto
Recruiting

Official title: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC) · Verastem, Inc.

Comparing Everolimus with Zanzalintinib for pancreatic neuroendocrine tumor (pnet)

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Everolimus. Group B receives Zanzalintinib.

Sites in London, Ottawa and 1 more city

Phase 2
2 groups
Sites in London, Ottawa and 1 more city
Recruiting

Official title: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor (pNET) · Exelixis

Testing daraxonrasib for pancreatic cancer

Explore this study →

There are 2 groups in this study. Group A receives daraxonrasib. Group B receives no study treatment and is followed for comparison.

Sites in Montreal and Toronto

Phase 3
2 groups
Sites in Toronto and Montreal
Recruiting

Official title: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer · Revolution Medicines, Inc.

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for pancreatic cancer.

Testing Biospecimen Collection with Computed Tomography for metastatic pancreatic neuroendocrine tumor

Explore this study →

Everyone in this study receives Sunitinib Malate and Lutetium Lu 177 Dotatate, together with one or more of: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging and Positron Emission Tomography.

One site, in Toronto

Phase 1
1 group
One site, in Toronto
Recruiting

Official title: Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor · National Cancer Institute (NCI)

Testing 68Ga-NNS309 with 177Lu-DFC413 for pancreatic ductal adenocarcinoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: 68Ga-NNS309 and 177Lu-DFC413.

One site, in Montreal

Phase 1
1 group
One site, in Montreal
Recruiting

Official title: Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Pancreatic Ductal Adenocarcinoma · Novartis Pharmaceuticals

Comparing 3 approaches for pancreatic cancer

Explore this study →

There are 3 groups in this study. Group A receives daraxonrasib. Group B receives daraxonrasib, gemcitabine and nab-paclitaxel. Group C, the comparison group, receives gemcitabine and nab-paclitaxel.

Sites in Toronto and Montreal

Phase 3
3 groups
Sites in Toronto and Montreal
Recruiting

Official title: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer · Revolution Medicines, Inc.

Comparing Gemcitabine with Dose-escalated Radiation Therapy for locally advanced unresectable pancreatic ductal

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy and Tumor Treating Fields Therapy. Group B receives one or more of: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Magnetic Resonance Imaging, Positron Emission Tomography and Questionnaire Administration.

One site, in Edmonton

Phase 3
2 groups
One site, in Edmonton
Recruiting

Official title: Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma · NRG Oncology

Comparing Cobimetinib with Ponatinib for pancreatic ductal carcinoma

Explore this study →

There are 2 groups in this study. Groups A and B receive one or more of: Cobimetinib, Ponatinib, Brigatinib, Colchicine, Selinexor, Abemaciclib, Neratinib, Doxorubicin, Etoposide and Ceritinib.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Using Tumor Models to Determine Treatments

Pancreatic Ductal Carcinoma · University Health Network, Toronto

Testing enoxaparin/tinzaparin/dalteparin for pancreas cancer

Explore this study →

There are 2 groups in this study. Group A receives enoxaparin/tinzaparin/dalteparin. Group B receives no study treatment and is followed for comparison.

One site, in Toronto

Phase 4
2 groups
One site, in Toronto
Recruiting

Official title: Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery

Pancreas Cancer · Helsinki University Central Hospital

Comparing 3 approaches for pancreatic cancer

Explore this study →

There are 3 groups in this study. Group A receives one or more of: Durvalumab, Gemcitabine, Nab paclitaxel, Tremelimumab and Propranolol. Group B receives one or more of: Durvalumab, Tremelimumab and Propranolol. Group C receives one or more of: Durvalumab, Gemcitabine, Tremelimumab, Propranolol and Cisplatin.

One site, in Edmonton

Phase 2
3 groups
One site, in Edmonton
Recruiting

Official title: Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Pancreatic Cancer · AHS Cancer Control Alberta

Comparing 3 approaches for pancreatic ductal adenocarcinoma

Explore this study →

There are 3 groups in this study. Groups A and C receive LY3962673. Group B receives LY3962673, together with one or more of: Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan and 5-fluorouracil.

Sites in Ottawa and Toronto

Phase 1
3 groups
Sites in Ottawa and Toronto
Recruiting

Official title: MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Pancreatic Ductal Adenocarcinoma · Eli Lilly and Company

Testing [68Ga]Ga-NNS309 with [177Lu]Lu-NNS309 for pancreatic ductal adenocarcinoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: [68Ga]Ga-NNS309 and [177Lu]Lu-NNS309.

Sites in Montreal and Toronto

Phase 1
1 group
Sites in Toronto and Montreal
Recruiting

Official title: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Pancreatic Ductal Adenocarcinoma · Novartis Pharmaceuticals

Testing WEF-001 for advanced or metastatic KRAS-mutant tumor in pancreatic

Explore this study →

Everyone in this study is in one group and receives WEF-001.

One site, in Toronto

Phase 1
1 group
One site, in Toronto
Recruiting

Official title: Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma · Auricula Biosciences Inc.

Testing mFOLFIRINOX with Gemcitabine / Nab-paclitaxel for pancreatic adenocarcinoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: mFOLFIRINOX and Gemcitabine / Nab-paclitaxel.

One site, in Hamilton

Phase 2
1 group
One site, in Hamilton
Recruiting

Official title: Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

Pancreatic Adenocarcinoma · Hamilton Health Sciences Corporation

Testing Durvalumab with Oleclumab for pancreatic ductal adenocarcinoma

Explore this study →

Everyone in this study receives Durvalumab and Oleclumab.

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Durvalumab and Oleclumab in Resectable PDAC

Pancreatic Ductal Adenocarcinoma · University Health Network, Toronto

Comparing Autogene cevumeran with mFOLFIRINOX for pancreatic ductal adenocarcinoma

Explore this study →

There are 2 groups in this study. Group A receives Autogene cevumeran, Atezolizumab and mFOLFIRINOX. Group B, the comparison group, receives mFOLFIRINOX.

Sites in Montreal and Toronto

Phase 2
2 groups
Sites in Toronto and Montreal
Recruiting

Official title: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Adenocarcinoma, Pancreatic Ductal · Genentech, Inc.

Testing Fecal Microbiota Transplantation with PEG3350 for unresectable or metastatic advanced pancreatic ductal

Explore this study →

Everyone in this study receives Fecal Microbiota Transplantation, together with one or more of: PEG3350, Gemcitabine and nab-Paclitaxel.

One site, in London

Phase 1
1 group
One site, in London
Recruiting

Official title: CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma · John Lenehan

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Pancreatic Cancer trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.